Prostate cancer (CaP) progresses from a hormone dependent to refractory state. Hormone ablation therapy remains the single most effective treatment for early stage CaP. Unfortunately, most tumors relapse and become androgen-refractory or independent. The prognosis for the latter stage remains poor and no effective treatment is in sight. There is thus, an urgent need for understanding the progression factors that lead to androgen-refractory status, with the hope that some of these factors could be targets for therapy in the future. Considering the heterogeneous nature of CaP, there are likely different progression factors that allow cells to grow without the need for androgen; some may activate an autonomous growth pathway, bypassing the androgen receptor, while others may activate androgen receptors, bypassing androgen. In this proposal, we focus on neurotrophic factors or neuropeptides, which are known to be released by advanced prostate cancers and have been implicated in the development of the androgen-independent state. We have obtained preliminary data demonstrating that these factors can substitute for androgen to stimulate the growth of androgen dependent CaP cells, both in vitro and in vivo. They do so by activating androgen receptor in the absence of androgen and by engaging a signal complex consisting of non-receptor tyrosine kinases FAK, Src and Etk. Tyrosine kinases, while a minor class of protein kinases, represent a major class of oncogenes. The PI's lab has had extensive experience in studying tyrosine kinases. All three kinases described above have been shown to possess oncogemc properties, and Etk was originally co-discovered in the PI's lab from CaP cells. This kinase, by virtue of having a PH, a SH3 and a SH2 domain serves as an active enzyme as well as a scaffold protein. We believe this is the first time that a molecular link between G-protein coupled receptors, to which neurotrophic factors bind, and nuclear receptors, to which androgen binds, was demonstrated. There are two specific aims of this proposal: 1) To characterize the role of tyrosine kinase in neuropeptide signaling and 2) To characterize the role of kinase signaling in androgen receptor activation.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK052659-05
Application #
6624360
Study Section
Special Emphasis Panel (ZRG1-UROL (01))
Program Officer
Rankin, Tracy L
Project Start
1997-07-24
Project End
2007-03-31
Budget Start
2003-04-01
Budget End
2004-03-31
Support Year
5
Fiscal Year
2003
Total Cost
$310,319
Indirect Cost
Name
University of California Davis
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Guo, W; Liu, R; Bhardwaj, G et al. (2014) Targeting Btk/Etk of prostate cancer cells by a novel dual inhibitor. Cell Death Dis 5:e1409
Guo, Wenchang; Liu, Ruiwu; Bhardwaj, Gaurav et al. (2013) CTA095, a novel Etk and Src dual inhibitor, induces apoptosis in prostate cancer cells and overcomes resistance to Src inhibitors. PLoS One 8:e70910
Wang, L-Y; Kung, H-J (2012) Male germ cell-associated kinase is overexpressed in prostate cancer cells and causes mitotic defects via deregulation of APC/CCDH1. Oncogene 31:2907-18
Guo, Wenchang; Liu, Ruiwu; Ono, Yoko et al. (2012) Molecular characteristics of CTA056, a novel interleukin-2-inducible T-cell kinase inhibitor that selectively targets malignant T cells and modulates oncomirs. Mol Pharmacol 82:938-47
Kung, Hsing-Jien (2011) Targeting tyrosine kinases and autophagy in prostate cancer. Horm Cancer 2:38-46
Wu, Zhaoju; Chang, Pei-Ching; Yang, Joy C et al. (2010) Autophagy Blockade Sensitizes Prostate Cancer Cells towards Src Family Kinase Inhibitors. Genes Cancer 1:40-49
Hsia, Datsun A; Tepper, Clifford G; Pochampalli, Mamata R et al. (2010) KDM8, a H3K36me2 histone demethylase that acts in the cyclin A1 coding region to regulate cancer cell proliferation. Proc Natl Acad Sci U S A 107:9671-6
Kung, Hsing-Jien; Evans, Christopher P (2009) Oncogenic activation of androgen receptor. Urol Oncol 27:48-52
Purnell, Phillip R; Mack, Philip C; Tepper, Clifford G et al. (2009) The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells. J Thorac Oncol 4:448-54
Kim, Randie H; Bold, Richard J; Kung, Hsing-Jien (2009) ADI, autophagy and apoptosis: metabolic stress as a therapeutic option for prostate cancer. Autophagy 5:567-8

Showing the most recent 10 out of 22 publications